Toxicities and response rate in stage II non-small cell lung cancer patients receiving paclitaxel-cisplatin One-year observational study

Background: The patients undergoing cancer treatment are experiencing a wide range of toxicity. This study is on cancer patients diagnosed with stage II non-small cell lung cancer (NSCLC). Aim and Objective: The primary objective was to study and grade the various toxicities of paclitaxel (PTX) c...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Anu Chandran, Paul Mathai, Laveesh Raveendran, Varun Raghavan, Premlal K S
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Eldaghayes Publisher 2021-01-01
coleção:	National Journal of Physiology, Pharmacy and Pharmacology
Assuntos:	cancer treatment; drug toxicity profile; lung cancer; national securities clearing corporation ltd.; paclitaxel-cisplatin regimen stage ii non-small cell lung cancer; the world health organizations toxicity criteria
Acesso em linha:	http://www.ejmanager.com/fulltextpdf.php?mno=27762
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!